Literature DB >> 17587073

Prevalence, microbiology, and clinical characteristics of extended-spectrum beta-lactamase-producing Enterobacter spp., Serratia marcescens, Citrobacter freundii, and Morganella morganii in Korea.

S-H Choi1, J E Lee, S J Park, M-N Kim, E J Choo, Y G Kwak, J-Y Jeong, J H Woo, N J Kim, Y S Kim.   

Abstract

We examined the prevalence and characteristics of extended-spectrum beta-lactamase (ESBL)-producing clinical isolates among Enterobacter spp., Serratia marcescens, Citrobacter freundii, and Morganella morganii, and evaluated screening criteria, clinical characteristics and outcomes of infections caused by ESBL-producing organisms. Between January and June 2005, a total of 493 nonduplicate consecutive isolates were collected at Asan Medical Center, a 2,300-bed tertiary hospital in Seoul, Republic of Korea. Fifty isolates (10.1%) were positive for phenotypical ESBL-test. The positive rate of phenotypical ESBL-test in Enterobacter spp., S. marcescens, C. freundii, and M. morganii was 12.8%, 12.4%, 4.9%, and 0% respectively. SHV-12 (18 isolates), CTX-M-9 (17 isolates), and TEM-52 (five isolates) were the most prevalent ESBL types. The ESBL in 17 strains could not be identified. As an ESBL screening criterion, the cefepime MIC >or=1 microg/ml had the highest sensitivity (0.84) and specificity (0.87). Half of the ESBL-producing isolates (25/50) were judged as pathogens. Cholangitis (ten cases), and pneumonia (six cases) were the most common infections. The overall mortality was 12.0%.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17587073     DOI: 10.1007/s10096-007-0308-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  High prevalence of extended-spectrum beta-lactamase-producing strains among blood isolates of Enterobacter spp. collected in a tertiary hospital during an 8-year period and their antimicrobial susceptibility patterns.

Authors:  Hyunjoo Pai; Jung Yun Hong; Jeong-Hum Byeon; Yun-Kyung Kim; Hoan-Jong Lee
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

2.  Prevalence of derepressed ampC mutants and extended-spectrum beta-lactamase producers among clinical isolates of Citrobacter freundii, Enterobacter spp., and Serratia marcescens in Korea: dissemination of CTX-M-3, TEM-52, and SHV-12.

Authors:  Jungmin Kim; Yu-Mi Lim
Journal:  J Clin Microbiol       Date:  2005-05       Impact factor: 5.948

3.  Detection and characterization of extended-spectrum beta-lactamases among bloodstream isolates of Enterobacter spp. in Hong Kong, 2000-2002.

Authors:  P L Ho; Ricky H L Shek; K H Chow; R S Duan; Gannon C Mak; Eileen L Lai; W C Yam; Kenneth W Tsang; W M Lai
Journal:  J Antimicrob Chemother       Date:  2005-01-28       Impact factor: 5.790

4.  Emergence of resistance to cefamandole: possible role of cefoxitin-inducible beta-lactamases.

Authors:  C C Sanders; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1979-06       Impact factor: 5.191

5.  Detection of extended-spectrum beta-lactamases in clinical isolates of Klebsiella pneumoniae and Escherichia coli.

Authors:  G A Jacoby; P Han
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

6.  In vitro antagonism of beta-lactam antibiotics by cefoxitin.

Authors:  C C Sanders; W E Sanders; R V Goering
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

7.  Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study.

Authors:  G Zanetti; F Bally; G Greub; J Garbino; T Kinge; D Lew; J-A Romand; J Bille; D Aymon; L Stratchounski; L Krawczyk; E Rubinstein; M-D Schaller; R Chiolero; M-P Glauser; A Cometta
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

8.  Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy.

Authors:  J W Chow; M J Fine; D M Shlaes; J P Quinn; D C Hooper; M P Johnson; R Ramphal; M M Wagener; D K Miyashiro; V L Yu
Journal:  Ann Intern Med       Date:  1991-10-15       Impact factor: 25.391

9.  Utility of NCCLS guidelines for identifying extended-spectrum beta-lactamases in non-Escherichia coli and Non-Klebsiella spp. of Enterobacteriaceae.

Authors:  Mitchell J Schwaber; Patti M Raney; J Kamile Rasheed; James W Biddle; Portia Williams; John E McGowan; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

10.  High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients.

Authors:  K Goethaert; M Van Looveren; C Lammens; H Jansens; A Baraniak; M Gniadkowski; K Van Herck; P G Jorens; H E Demey; M Ieven; L Bossaert; H Goossens
Journal:  Clin Microbiol Infect       Date:  2006-01       Impact factor: 8.067

View more
  15 in total

Review 1.  A Primer on AmpC β-Lactamases: Necessary Knowledge for an Increasingly Multidrug-resistant World.

Authors:  Pranita D Tamma; Yohei Doi; Robert A Bonomo; J Kristie Johnson; Patricia J Simner
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

2.  Bacteremia due to extended-spectrum-beta-lactamase-producing Enterobacter cloacae: role of carbapenem therapy.

Authors:  Ching-Chi Lee; Nan-Yao Lee; Jing-Jou Yan; Hsin-Chun Lee; Po-Lin Chen; Chia-Ming Chang; Chi-Jung Wu; Nai-Ying Ko; Li-Rong Wang; Chih-Hsien Chi; Wen-Chien Ko
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 3.  Serratia infections: from military experiments to current practice.

Authors:  Steven D Mahlen
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

4.  The opportunistic pathogen Serratia marcescens utilizes type VI secretion to target bacterial competitors.

Authors:  Sarah L Murdoch; Katharina Trunk; Grant English; Maximilian J Fritsch; Ehsan Pourkarimi; Sarah J Coulthurst
Journal:  J Bacteriol       Date:  2011-09-02       Impact factor: 3.490

5.  Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007.

Authors:  Stephen P Hawser; Samuel K Bouchillon; Daryl J Hoban; Robert E Badal; Po-Ren Hsueh; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

Review 6.  Epidemiology and genetics of CTX-M extended-spectrum β-lactamases in Gram-negative bacteria.

Authors:  Wei-Hua Zhao; Zhi-Qing Hu
Journal:  Crit Rev Microbiol       Date:  2012-06-15       Impact factor: 7.624

7.  The clonal relationship among the Citrobacter freundii isolated from the main hospital in Kermanshah, west of Iran.

Authors:  Mansour Rezaei; Alisha Akya; Azam Elahi; Keyghobad Ghadiri; Somayeh Jafari
Journal:  Iran J Microbiol       Date:  2016-06

8.  Extended Spectrum beta-Lactamases among Gram-Negative Bacterial Isolates from Clinical Specimens in Three Major Hospitals in Northern Jordan.

Authors:  Raymond G Batchoun; Samer F Swedan; Abdullah M Shurman
Journal:  Int J Microbiol       Date:  2009-09-10

9.  New secreted toxins and immunity proteins encoded within the Type VI secretion system gene cluster of Serratia marcescens.

Authors:  Grant English; Katharina Trunk; Vincenzo A Rao; Velupillai Srikannathasan; William N Hunter; Sarah J Coulthurst
Journal:  Mol Microbiol       Date:  2012-09-27       Impact factor: 3.501

10.  Prevalence and impact of extended-spectrum β-lactamase production on clinical outcomes in cancer patients with Enterobacter species bacteremia.

Authors:  Sun Jong Kim; Ki-Ho Park; Jin-Won Chung; Heungsup Sung; Seong-Ho Choi; Sang-Ho Choi
Journal:  Korean J Intern Med       Date:  2014-08-28       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.